Aspirin for acute stroke of unknown etiology in resource-limited settings A decision analysis

Neurology

Volumn 83, Issue 9, 2014, Pages 787-793

  Berkowitz, Aaron L ^a   Westover, M Brandon ^a   Bianchi, Matt T ^a   Chou, Sherry H Y ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE STROKE OF UNKNOWN ETIOLOGY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; IDIOPATHIC DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); NEUROIMAGING; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; ADULT; DECISION SUPPORT SYSTEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84908658710     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000730     Document Type: Article

References (27)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990- 2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245-255.
2. Brainin M, Teuschl T, Kalra L. Acute treatment and longterm management of stroke in developing countries. Lancet Neurol 2007;6:553-561.
3. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modeling. Lancet Neurol 2009;8:345-354.
4. Chen ZM, Sandercock P, Pan HC, Counell C, Collins R, Liu LS. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40, 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000;31:1240-1249.
5. Johnson ES, Lanes S, Wentworth C, Satterfield M, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999;159:1248-1253.
6. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA 1998;280:1930-1935.
7. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet 2011;378:1231-1243.
8. Runchey S, McGee S. Does this patient have a hemorrhagic stroke? Clinical findings distinguishing hemorrhagic stroke from ischemic stroke. JAMA 2010;303:2280-2286.
9. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987;316:250-258.
10. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003;34: 1710-1716.
11. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19, 435 patients with acute ischemic stroke. Lancet 1997;349: 1569-1581.
12. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
13. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010;376:112-123.
14. Zenebe G, Alemayehu M, Asmera J. Characteristics and outcomes of stroke at Tikur Anbessa Teaching Hospital, Ethiopia. Ethiop Med J 2005;43:251-259.
15. Matuja W, Janabi M, Kazema R, Mashuke D. Stroke subtypes in black Tanzanians: A retrospective study of computerized tomography scan diagnoses at Muhimbili National Hospital, Dar es Salaam. Trop Doct 2004;34:144-146.
16. Nyame PK, Jumah KB, Adjei S. Computerised tomographic scan of the head in evaluation of stroke in Ghanians. East Afr Med J 1998;75:637-639.
17. Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke 2007;2:17-26.
18. Berkowitz AL, Mittal M, Mclane HC, et al. Worldwide reported use of IV-tissue plasminogen activator for acute ischemic stroke. Int J Stroke 2014;9:349-355.
19. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review. Lancet Neurol 2009;8:355-369.
20. Ogata T, Yasaka M, Wakugawa Y, Inoue T, Ibayashi S, Okada Y. Deep venous thrombosis after acute intracerebral hemorrhage. J Neurol Sci 2008;272:83-86.
21. Thompson BB, Bejot Y, Caso V, et al. Prior antiplatelet use and outcome following intracerebral hemorrhage. Neurology 2010;75:1333-1342.
22. Flynn R, MacDonald TM, Murray GD, MacWalter RS, Doney ASF. Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage. Stroke 2010; 41:2606-2611.
23. Garbusinski JM, van der Sande MA, Bartholome EJ, et al. Stroke presentation and outcome in developing countries: A prospective study in the Gambia. Stroke 2005;36: 1388-1393.
24. The World Bank. World Development Indicators 1997. Washington, DC: IEC Information Center, Development Data Group; 1997.
25. Chow FC, Marra CM, Cho TA. Cerebrovascular disease in central nervous system infections. Semin Neurol 2011; 31:286-306.
26. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage incidence and time course. Stroke 1996;27: 1783-1787.
27. Berkowitz AL, Westover MB, Bianchi MT, Chou SH. Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings: A decision analysis. Neurology (in press 2014).